Evidence Hub

Use of echinocandins combined with clindamycin in Pneumocystis pneumonia: a case series of 14 patients

Idoia Bilbao, Iñigo Pineda Abel de la Cruz, Francisco de Asís Carmona-Torre, M. Rodríguez-Mateos, José Ramón Yuste Ara, J. D. del Pozo

Journal of Antimicrobial Chemotherapy, 2024

14 participants · 4 citations

Abstract

BACKGROUND

Pneumocystis jirovecii pneumonia (PcP) is an opportunistic infection for which the standard of care is co-trimoxazole. However, safety concerns and intolerance may compromise its utility.

OBJECTIVES

To evaluate the safety and efficacy of the combination of echinocandins and clindamycin to treat PcP.

PATIENTS AND METHODS

We investigated 14 patients treated with a co-trimoxazole-free combined regimen that included echinocandins and clindamycin.

RESULTS

Clinical cure was achieved in 8 out of 14 patients, while 5 had a fatal outcome due to their primary disease; however, only one patient died due to PcP.

CONCLUSIONS

Echinocandin and clindamycin may be a safe and effective alternative treatment for patients who cannot be given co-trimoxazole for PcP.

How strong is the evidence?

Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 14 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free